LifeTech Scientific Corporation
先健科技公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1302)

(1) RE-DESIGNATION OF DIRECTOR; (2) CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE AND THE REMUNERATION COMMITTEE; AND (3) GRANT OF WAIVER FROM STRICT COMPLIANCE WITH THE LISTING RULES

RE-DESIGNATION OF DIRECTOR

Reference is made to the announcements of LifeTech Scientific Corporation (the "**Company**") dated 26 January 2026 (the "**Resignation Announcement**") and 24 April 2026 (the "**Extension Announcement**") in relation to, among other things, the resignation of Mr. WANG Wansong ("**Mr. Wang**") as an independent non-executive Director of the Company. Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the Resignation Announcement and the Extension Announcement.

The Board hereby announces that Mr. JIANG Feng ("**Mr. Jiang**") has been redesignated from a non-executive Director to an independent non-executive Director and has been appointed as a member of each of the Audit Committee and the Remuneration Committee with effect from 18 June 2026.

Reasons for the Re-designation

Mr. Jiang was appointed as a non-executive Director with effect from 1 April 2014. The decision to appoint Mr. Jiang as a non-executive Director, instead of an independent non-executive Director in 2014 was driven by the Board's assessment of its strategic needs and Board composition at the time of the appointment. Since Mr. Jiang's appointment to the Board, other than his role as a non-executive Director, he has not been an employee of the Company or any of its subsidiaries, has not been involved in the Company's day-to-day management, and has not had any material financial or business relationship with the Company other than his directorship and the receipt of his director's fee. Notwithstanding that he had been designated as a non-executive Director at the time of his appointment, he has carried on his role and responsibilities on the Board as if he was an independent non-executive Director, providing oversight, objective challenges and advice in a non-executive Director capacity. Mr. Jiang fulfils all of the indicative criteria of independence set out in Rule 3.13 of the Listing Rules.

Biographical information on Mr. Jiang

Mr. JIANG Feng (姜峰), aged 63, was appointed as a non-executive Director on 1 April 2014. Mr. Jiang is currently vice president of China Association for Medical Devices Industry, chairman of China Strategic Alliance of Medical Devices Innovation, deputy director of Biomedical Engineering Education Steering Committee of the Ministry of Education (教育部生物醫學工程專業教育指導委員會) and chairman of TC94 sub-committee of National Standards Technical Committee (國家標準技術委員會).

Mr. Jiang had been working as a clinician for 12 years before he left the hospital in 1997 to establish his own business. For his outstanding achievements, Mr. Jiang was considered to be a special talent by SASAC and was chosen to be a leader of national large medicine and device companies for a long term, including as chairman and general manager of China National Pharmaceutical Group Corporation North West Company and China National Medical Equipment Co., Ltd. During that period, Mr. Jiang was in charge of or participated in restructuring, mergers and acquisitions and transformations for the listing of nearly 40 relevant companies.

Mr. Jiang served as a general manager of China National Medical Equipment Co., Ltd. for 9 years, during which he accomplished the substantial transformation of the enterprise from an exhibition business to the production and operation of medical devices by establishing China's first Sino-foreign joint venture medical device distribution company and making it the largest domestic medical device distributor within 5 years. Mr. Jiang had been president and standing vice president of China Association for Medical Devices Industry for 23 years, during which he visited and evaluated over a thousand of member enterprises. For around 16 years as a chairman of China Strategic Alliance of Medical Devices Innovation, he has been assisting the science and technology department and local science and technology bureaus in assessing subjects of hundreds of medical device projects and conducting subsequent management.

Benefiting from his extensive work experience in the industry, Mr. Jiang is expert at the operation and management of medical companies and understands development trends of the industry, particularly in industrial innovation and international marketing. Since 8 November 2016, Mr. JIANG was appointed as an independent nonexecutive director of Hangzhou Kangji Medical Instrument Co., Ltd. for a term of three years. Since December 2022, Mr. JIANG was appointed as an independent director of Dynamiker Biotechnology (Tianjin) Co., Ltd. and resigned in June 2023. Since April 2023, Mr. Jiang has been appointed as an independent director of SWS Hemodialysis Care Co., Ltd. Since September 2023, Mr. Jiang has been appointed as an independent director of Inkon Life Technology Co., Ltd.

Mr. Jiang graduated from the Fourth Military Medical University with a bachelor's degree in Medicine in 1985 and obtained his doctoral degree in clinical surgery in 1995 from the Fourth Military Medical University. He obtained an EMBA degree from Tsinghua University in 2007.

Mr. Jiang has entered into an appointment letter with the Company for his appointment as an independent non-executive Director for a term of three years commencing from 18 June 2026, subject to early termination as provided thereunder and to retirement by rotation and re-election in accordance with the Listing Rules and the articles of association of the Company. Under the aforesaid letter of appointment, Mr. Jiang will receive a director's fee of RMB180,000 per annum. The remuneration of Mr. Jiang has been determined with reference to the prevailing market conditions, his role and responsibilities and the Company's remuneration policy. Such remuneration has been recommended by the Remuneration Committee and approved by the Board and will be reviewed by the Remuneration Committee and the Board on an annual basis.

As at the date of this announcement, save as disclosed above, Mr. Jiang has confirmed that he (i) does not hold any other position in the Company or any of its subsidiaries, nor served as a director of any public company with securities listed on any securities market in Hong Kong or overseas in the past three years and does not have other major appointments and professional qualifications; (ii) has no relationship with any Directors, senior management, substantial shareholders (as defined under the Listing Rules) or controlling shareholders (as defined under the Listing Rules) of the Company; and (iii) nor does he have any interest in the shares of the Company which is required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

As at the date of this announcement, Mr. Jiang has confirmed that he (i) meets the independence requirements as set out in Rule 3.13 of the Listing Rules; (ii) has no past or present financial or other interest in the business of the Company or its subsidiaries, and is not connected with any core connected persons (as defined in the Listing Rules) of the Company; and (iii) is not subject to any other factors that may affect his independence at the time of his re-designation.

Save as disclosed above, Mr. Jiang is not aware of any other matters that are required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules or any other matters that need to be brought to the attention of the shareholders of the Company.

CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE AND THE REMUNERATION COMMITTEE

The Board hereby further announces, after consideration and approval by the Nomination Committee and the Board, Mr. Jiang has been appointed as a member of each of the Audit Committee and the Remuneration Committee with effect from 18 June 2026.

GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULES 3.10(1), 3.11, 3.21, 3.23, 3.25, 3.27, 3.27A AND 3.27C OF THE LISTING RULES

As disclosed in the Resignation Announcement, following the resignation of Mr. Wang, the Company only has two independent non-executive Directors. The number of independent non-executive Directors and number of members of each of the Audit Committee, Nomination Committee and Remuneration Committee falls below the number required under Chapter 3 of the Listing Rules.

As disclosed in the Extension Announcement, pursuant to Rule 3.11 of the Listing Rules, the Company should appoint an additional independent non-executive Director within three months after failing to meet the requirements under Rule 3.10(1) of the Listing Rules. In addition, pursuant to Rules 3.23, 3.27 and 3.27C of the Listing Rules, the Company should appoint appropriate members to the Audit Committee, Remuneration Committee and Nomination Committee within three months after failing to meet the requirements under Rules 3.21, 3.25 and 3.27A of the Listing Rules, respectively (i.e. on or before 26 April 2026, the "**Grace Period**"). Since the resignation of Mr. Wang on 26 January 2026 and during the Grace Period, the Company took steps to identify and evaluate potential independent non-executive Director candidates. However, the role of an independent non-executive Director requires candidates who possess the requisite qualifications, experience and expertise, and who can satisfy the independence requirements under Rule 3.13 of the Listing Rules. The pool of suitable candidates is limited. Further, the Grace Period also coincided with several public holidays and festival periods, as well as the period during which the Company was occupied with the preparation of its annual results announcement, annual report and annual general meeting, which limited the available resources to progress the independent non-executive Director search during this period.

In light of the above, the Company applied to the Stock Exchange for a waiver from strict compliance with Rules 3.10(1), 3.11, 3.21, 3.23, 3.25, 3.27, 3.27A and 3.27C of the Listing Rules to extend the Grace Period.

The Stock Exchange has granted the waiver to the Company to extend the grace period to 19 June 2026 or the effective date of re-designation of Mr. Jiang as the Company's independent non-executive Director, whichever is earlier, to re-comply with Rules 3.10(1), 3.11, 3.21, 3.23, 3.25, 3.27, 3.27A and 3.27C.

Following the re-designation of Mr. Jiang: (i) the Board has three independent non-executive Directors, representing more than one-third of the Board; and (ii) each of the Audit Committee, the Nomination Committee and the Remuneration Committee has three members, and is each constituted by a majority of independent non-executive Directors. Accordingly, the Company has fully complied with the requirements under Rules 3.10(1), 3.11, 3.21, 3.23, 3.25, 3.27, 3.27A and 3.27C of the Listing Rules.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman
and Chief Executive Officer

Hong Kong, 18 June 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu being executive Directors; and Mr. ZHOU Luming, Ms. CHEN Dongxia and Mr. JIANG Feng being independent non-executive Directors.